PF 07275315
Alternative Names: anti-IL4/13/TSLP - Pfizer; PF-07275315Latest Information Update: 14 Jun 2024
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 13 May 2024 Pfizer completes a phase I trial in Atopic dermatitis (In volunteers) in USA and Belgium (IV) (SC) (NCT05411588)
- 06 Sep 2023 Phase-II clinical trials in Atopic dermatitis in USA (SC) (NCT05995964)
- 16 Aug 2023 Pfizer plans a phase II trial for atopic dermatitis in the USA (SC, Injection) (NCT05995964)